| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |